No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
183 |
4. Check minimum number of eventsNone |
183 |
5. Include endpointsNone |
183 |
6. Filter based on genotype QC (FinnGen only) |
172 |
Control definitions (FinnGen only)
- Control exclude
- H7_VISUALDISTBLIND
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- H54
- Name in latin
- Amblyopia non specificata oculorum amborum
Similar endpoints
↥List of similar endpoints to
Mild or no visual impairment, binocular
based on the number of shared cases.
Similar with more cases:
- Visual impairment including blindness (binocular or monocular)
- Visual disturbances and blindness
- Diseases of the eye and adnexa
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1613 | 870 | 732 |
| Only index persons | 1433 | 791 | 642 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.02 | 0.02 |
| Only index persons | 0.03 | 0.03 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 42.74 | 48.39 | 35.96 |
| Only index persons | 44.24 | 49.24 | 38.09 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 172 | 118 | 54 |
| Unadjusted period prevalence (%) | 0.04 | 0.04 | 0.02 |
| Median age at first event (years) | 55.70 | 53.01 | 61.58 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 183
- Matched controls
- 1830
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
H54.3
ICD-10 Finland
Mild or no visual impairment, binocular
+∞
264.8
183
*
XCK00
NOMESCO Finland
Perimetry
18.2
57.8
52
39
H54.2
ICD-10 Finland
Moderate visual impairment, binocular
+∞
37.8
35
*
XCW99
NOMESCO Finland
Other investigative procedure of eye
8.8
34.3
51
77
H53.4
ICD-10 Finland
Visual field defects
185.3
30.7
31
*
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
6.9
29.9
57
112
Z3229
NOMESCO Finland
Other healthcare associate professional
7.2
26.8
47
84
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
7.3
24.3
41
70
CK2S4
NOMESCO Finland
Plain photography of ocular fundus
8.7
24.2
34
47
Z01.0
ICD-10 Finland
Examination of eyes and vision
5.2
24.1
68
188
H53.1
ICD-10 Finland
Subjective visual disturbances
26.3
22.6
31
14
CK2X4
NOMESCO Finland
Optical coherence tomography (OCT) of ocular fundus
6.2
21.2
42
84
XCK10
NOMESCO Finland
Photography of fundus of eye
6.0
20.1
41
84
H47.2
ICD-10 Finland
Optic atrophy
+∞
19.1
18
*
XCD10
NOMESCO Finland
Electrophysiological examination of eye
20.9
18.4
27
15
ZXA10
NOMESCO Finland
Bilateral
4.0
16.2
60
198
N03AG01
ATC
valproic acid; systemic, rectal
6.4
16.1
29
52
R56.8
ICD-10 Finland
Other and unspecified convulsions
6.4
13.6
24
42
SPAT1229
SPAT
Assessment of need for aid
5.9
13.4
26
50
111
Kela drug reimbursment
Epilepsy and comparable convulsive disorders
6.4
13.1
23
40
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.1
12.6
101
524
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
13.8
12.5
21
17
R4120
NOMESCO Finland
Occupational therapy
5.3
11.6
25
53
H35.5
ICD-10 Finland
Hereditary retinal dystrophy
127.7
11.6
12
*
H54.7
ICD-10 Finland
Unspecified visual loss
37.6
11.4
14
*
TAB00
NOMESCO Finland
Lumbar puncture
6.0
11.2
21
39
AA1AD
NOMESCO Finland
CT of head and brain
3.1
11.1
63
266
H04.10
ICD-10 Finland
Dry eye syndrome
3.9
10.7
36
109
H54.0
ICD-10 Finland
Blindness, binocular
+∞
10.5
10
*
N03AX14
ATC
levetiracetam; systemic
14.3
10.4
17
13
CS424
NOMESCO Finland
Visual field testing with Goldmann perimetry
42.6
10.1
12
*
Z2446
NOMESCO Finland
Social worker
4.3
9.9
28
74
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
5.1
9.8
22
48
R50.9
ICD-10 Finland
Fever, unspecified
3.2
9.3
44
165
ZXA00
NOMESCO Finland
Right side
2.8
9.2
63
290
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
3.6
9.2
34
109
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
4.5
9.1
24
60
CS444
NOMESCO Finland
Visual field testing with Octopus automated perimetry
8.3
8.9
19
25
A28
ICPC
Limited function/disability NOS
3.1
8.8
43
164
R4110
NOMESCO Finland
Physiotherapy
2.7
8.8
65
311
R5210
NOMESCO Finland
Assessment of the improvements needed in the living environment
52.6
8.8
10
*
H02AB06
ATC
prednisolone; systemic
2.5
8.7
102
609
N02AX02
ATC
tramadol; systemic, rectal
2.5
8.6
86
476
I69.3
ICD-10 Finland
Sequelae of cerebral infarction
4.2
8.6
24
63
R3120
NOMESCO Finland
Training in mobility skills
94.2
8.5
9
*
H53.0
ICD-10 Finland
Amblyopia ex anopsia
+∞
8.4
8
*
G40.9
ICD-10 Finland
Epilepsy, unspecified
8.8
8.3
17
21
CS494
NOMESCO Finland
Other visual field testing
12.5
8.2
14
12
Z3231
NOMESCO Finland
Registered nurse
2.5
8.2
70
358
N03AX09
ATC
lamotrigine; oral
4.7
8.2
20
47
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
3.9
8.0
25
71
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.5
8.0
76
407
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.2
8.0
36
131
H53.9
ICD-10 Finland
Visual disturbance, unspecified
11.5
7.9
14
13
I63.9
ICD-10 Finland
Cerebral infarction, unspecified
3.4
7.9
31
103
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
12.6
7.7
13
11
H53.2
ICD-10 Finland
Diplopia
26.3
7.7
10
*
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
4.8
7.6
18
41
WX408
NOMESCO Finland
General anesthesy, balanced
2.6
7.6
57
272
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
3.6
7.6
27
84
H54.1
ICD-10 Finland
Severe visual impairment, binocular
+∞
7.3
7
*
R42
ICD-10 Finland
Dizziness and giddiness
2.6
7.3
52
242
N99
ICPC
Neurological disease other
31.4
7.2
9
*
Z2221
NOMESCO Finland
Medical doctor
2.4
7.2
64
330
L28
ICPC
Limited function/disability (L)
2.8
7.0
42
178
R2120
NOMESCO Finland
Counselling and guidance concerning rehabilitation services and social security
41.6
6.8
8
*
H46
ICD-10 Finland
Optic neuritis
41.6
6.8
8
*
CA1CG
NOMESCO Finland
Eye and orbita extensive MRI examination with high intensity magnet
41.6
6.8
8
*
ZXD10
NOMESCO Finland
Scheduled procedure
2.3
6.8
80
464
WX140
NOMESCO Finland
Parabulbar anesthesy
6.3
6.8
17
29
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
2.8
6.8
39
162
F32.9
ICD-10 Finland
Depressive episode, unspecified
2.9
6.7
35
138
K90
ICPC
Stroke/cerebrovascular accident
10.6
6.6
12
12
N03AF02
ATC
oxcarbazepine; oral
6.1
6.6
17
30
Z3226
NOMESCO Finland
Physiotherapist
2.6
6.6
47
217
H55
ICD-10 Finland
Nystagmus and other irregular eye movements
72.3
6.5
7
*
ZXE00
NOMESCO Finland
One hour or less
2.2
6.4
82
490
XF400
NOMESCO Finland
ECG with 12 standard connections
2.7
6.3
38
161
G80.9
ICD-10 Finland
Cerebral palsy, unspecified
+∞
6.3
6
*
Y83
ICD-10 Finland
Surgical operation and other surgical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
3.6
6.2
21
63
TPH04
NOMESCO Finland
Cathetrisation of vein
2.4
6.2
49
238
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
3.2
6.1
25
85
S01XA20
ATC
artificial tears and other indifferent preparations; ophthalmic
2.2
6.1
84
514
Z01.8
ICD-10 Finland
Other specified special examinations
2.5
6.1
45
211
F32.2
ICD-10 Finland
Severe depressive episode without psychotic symptoms
3.5
6.1
22
69
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.3
6.1
57
298
Z03.9
ICD-10 Finland
Observation for suspected disease or condition, unspecified
2.6
6.0
41
185
R41.8
ICD-10 Finland
Other and unspecified symptoms and signs involving cognitive functions and awareness
3.2
6.0
25
86
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
114
668
2.87
10.82
7.8
6.2
1.21
1.22
mmol/l
0.88
101
573
129
816
2.97
10.43
7.8
4.3
6.66
6.50
mmol/l
0.33
121
753
100
556
2.76
10.37
4.7
4.3
35.89
35.77
g/l
0.08
93
525
103
601
2.63
9.41
7.9
5.8
1.21
1.22
mmol/l
0.68
95
552
50
202
3.03
9.33
1.9
1.9
—
—
—
0
0
102
601
2.58
9.01
12.2
11.4
1.28
1.21
inr
0.21
24
171
52
230
2.76
8.12
4.0
3.7
202.74
144.37
ng/l
0.16
39
164
28
88
3.58
7.77
5.2
4.6
0.25
1.74
mmol/l
0.81
19
66
64
327
2.47
7.37
2.1
2.1
—
—
—
0
0
7
0
+∞
7.34
1.0
0.0
—
—
—
0
0
77
431
2.36
7.20
3.2
2.2
50.34
68.78
u/l
1.02
68
401
12
12
10.60
6.64
1.2
1.0
—
—
—
0
0
94
592
2.21
6.45
2.6
2.4
75.09
76.59
nmol/l
0.18
85
531
86
524
2.21
6.40
2.2
1.9
97.67
96.26
pmol/l
0.09
46
263
35
142
2.81
6.33
5.3
5.3
0.97
1.03
mmol/l
0.03
28
112
34
138
2.80
6.14
1.8
1.8
—
—
—
0
0
117
830
2.14
5.63
11.8
9.2
4.45
4.01
e9/l
1.16
103
730
37
165
2.56
5.54
6.2
5.7
0.99
1.13
mmol/l
2.52
37
151
104
718
2.04
5.25
7.1
5.6
9.04
11.79
umol/l
2.75
93
685
24
88
2.99
5.18
7.7
6.3
24.42
24.81
mmol/l
0.26
24
88
33
144
2.58
5.15
1.9
1.9
—
—
—
0
0
20
67
3.23
5.00
1.8
1.6
—
—
—
0
0
139
1080
2.19
4.95
10.1
6.7
79.60
81.33
u/l
0.22
131
1008
16
48
3.56
4.73
1.7
2.0
—
—
—
0
0
136
1061
2.10
4.60
5.1
3.9
14.74
11.69
mm/h
1.18
120
975
15
44
3.62
4.57
1.8
1.8
—
—
—
0
0
28
120
2.57
4.52
2.1
2.2
0.22
0.22
g/l
0.08
28
115
9
13
7.22
4.21
1.1
1.2
—
—
—
0
0
10
18
5.81
4.03
1.2
1.1
—
—
—
0
0
10
18
5.81
4.03
1.2
1.1
—
—
—
0
0
53
312
1.98
3.99
2.3
1.9
1.18
1.38
mg/l
0.18
39
237
20
77
2.79
3.96
7.3
6.4
93.82
94.21
%
0.15
20
77
63
397
1.90
3.87
4.7
3.2
0.43
0.35
e6/l
0.20
46
289
70
460
1.84
3.76
5.1
3.8
25.04
22.34
ng/l
0.22
51
316
155
1308
2.21
3.74
19.4
11.6
82.99
83.95
ml/min/173m2
0.20
132
1043
52
318
1.89
3.46
3.1
2.9
324.22
11178.76
umol/l
2.51
46
271
120
943
1.79
3.42
5.0
2.8
48.21
41.25
u/l
0.44
110
890
72
489
1.78
3.41
4.9
3.3
—
—
—
0
0
31
161
2.11
3.24
4.3
2.6
5.28
8.49
umol/l
1.23
25
138
6
8
7.70
3.08
1.8
2.8
—
—
—
0
0
91
676
1.69
3.04
2.8
2.4
—
—
—
0
0
54
348
1.78
3.00
2.5
2.0
3.00
3.25
mg/l
0.35
46
306
41
243
1.89
2.97
3.8
3.0
0.37
0.89
e6/l
2.27
22
141
14
52
2.83
2.96
1.6
2.1
—
—
—
0
0
11
33
3.48
2.86
1.5
1.2
—
—
—
0
0
11
33
3.48
2.86
1.5
1.2
—
—
—
0
0
148
1271
1.86
2.78
6.4
5.2
40.18
39.36
mmol/mol
0.43
134
1191
163
1446
2.16
2.77
22.9
12.4
23.15
21.35
mg/l
0.29
144
1106
49
314
1.77
2.75
1.9
1.4
16.55
22.63
nmol/l
2.37
44
272
32
179
1.95
2.74
2.6
2.1
2.39
2.42
g/l
0.09
27
164
52
340
1.74
2.72
3.0
3.3
1707.37
1221.84
ng/l
0.39
46
288
11
36
3.18
2.61
1.5
2.4
0.00
0.00
g/l
-0.00
11
36
20
95
2.24
2.60
1.5
1.6
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
11
37
3.10
2.53
2.4
2.4
0.44
0.34
u/ml
—
5
24
30
169
1.93
2.52
4.2
4.4
29.67
32.67
%
0.64
24
106
131
1112
1.63
2.28
5.4
4.0
14.47
14.63
pmol/l
0.29
115
1013
63
454
1.59
2.23
2.8
2.8
2.35
2.36
mmol/l
0.26
55
400
28
161
1.87
2.22
6.2
4.8
105.82
104.54
mmol/l
1.10
28
161
36
224
1.76
2.21
2.9
2.5
2.46
2.45
mmol/l
0.40
29
192
52
362
1.61
2.11
1.3
1.3
0.87
1.71
u/ml
—
6
89
36
228
1.72
2.08
4.1
3.1
1.85
2.59
e6/l
0.34
17
127
16
77
2.18
2.03
1.2
1.2
—
—
—
0
0
6
16
3.84
1.95
8.2
4.4
25.33
23.75
nmol/l
—
6
16
7
22
3.27
1.90
1.0
1.3
—
—
—
0
0
151
1352
1.67
1.87
6.3
4.7
1.83
1.86
mu/l
0.10
137
1239
37
245
1.64
1.82
1.8
1.7
1003.28
1140.40
nmol/l
0.48
26
194
6
18
3.41
1.76
1.2
1.2
—
—
—
0
0
26
159
1.74
1.70
8.5
6.7
—
—
—
0
0
7
25
2.87
1.66
1.1
1.0
—
—
—
0
0
81
648
1.45
1.66
3.7
2.6
104.11
91.42
ug/l
0.22
74
602
6
20
3.07
1.59
1.2
1.3
—
—
—
0
0
52
385
1.49
1.57
4.2
3.7
9.54
14.42
mg/mmol
0.43
33
236
5
16
3.18
1.44
1.4
1.4
—
—
—
0
0
5
16
3.18
1.44
1.2
1.6
—
—
—
0
0
6
22
2.78
1.44
1.0
1.0
—
—
—
0
0
7
29
2.47
1.40
1.4
1.4
—
—
—
0
0
14
76
1.91
1.34
7.7
5.8
24.61
24.74
mmol/l
0.05
14
70
9
43
2.15
1.32
1.3
1.7
—
—
—
0
0
48
363
1.44
1.29
1.6
1.6
1.51
1.33
mmol/l
0.65
40
314
6
25
2.45
1.25
1.2
1.6
2145.83
30234.63
e6/l
—
6
19
9
45
2.05
1.25
1.2
1.1
—
—
—
0
0
111
970
1.37
1.24
3.6
3.5
—
—
—
0
0
5
19
2.68
1.22
2.4
1.9
—
—
—
0
0
7
30
2.39
1.13
1.1
1.4
—
—
—
0
0
9
46
2.01
1.05
2.0
1.2
—
—
—
0
0
5
23
2.21
0.98
2.2
2.3
3.78
5.76
u/ml
—
5
23
19
126
1.57
0.96
3.2
3.6
—
—
—
0
0
169
1613
1.62
0.94
31.6
18.7
255.47
255.32
e9/l
0.01
169
1575
10
55
1.87
0.94
1.2
1.5
—
—
—
0
0
169
1615
1.61
0.91
32.1
18.6
4.44
4.48
e12/l
0.45
169
1570
169
1616
1.60
0.89
32.4
18.7
132.90
134.26
g/l
0.66
169
1591
6
31
1.97
0.85
1.0
1.5
—
—
—
0
0
6
32
1.90
0.82
1.3
1.4
—
—
—
0
0
0
25
0.00
0.79
0.0
2.8
—
78.95
—
0
15
145
1359
1.32
0.78
5.3
4.2
6.01
5.86
mmol/l
0.43
132
1249
6
34
1.79
0.77
1.7
1.6
—
—
—
0
0
147
1383
1.32
0.75
5.2
4.6
2.70
2.79
mmol/l
0.60
136
1282
16
109
1.51
0.74
11.5
7.4
7.78
9.27
mmol/l
0.55
16
104
5
25
2.03
0.73
1.6
1.4
—
—
—
0
0
7
40
1.78
0.72
1.4
1.4
—
—
—
0
0
5
27
1.87
0.69
1.2
1.9
—
—
—
0
0
8
129
0.60
0.66
1.5
1.6
—
—
—
0
0
5
30
1.68
0.62
4.6
3.0
67.20
60.70
%
—
5
30
0
20
0.00
0.60
0.0
3.0
—
88.99
—
0
20
10
64
1.60
0.60
1.8
2.0
—
—
—
0
0
138
1303
1.24
0.58
4.1
3.8
1.33
1.25
mmol/l
0.69
121
1202
6
38
1.60
0.55
1.7
1.9
—
—
—
0
0
6
38
1.60
0.55
1.2
1.9
—
—
—
0
0
31
252
1.28
0.54
1.3
1.3
12.72
41.70
iu/ml
—
5
92
77
694
1.19
0.51
4.5
3.8
0.00
0.00
estimate
-0.00
13
127
9
65
1.40
0.51
3.3
3.7
55.82
48.02
%
—
9
65
143
1364
1.22
0.49
4.6
4.2
4.57
4.68
mmol/l
0.68
132
1275
22
274
0.78
0.48
1.3
1.4
—
—
—
0
0
47
537
0.83
0.47
4.8
3.8
—
—
—
0
0
142
1357
1.21
0.45
4.5
4.1
1.44
1.51
mmol/l
1.03
128
1259
10
69
1.48
0.45
2.5
2.5
6094.22
5161.99
u/l
—
5
25
5
33
1.53
0.41
1.2
1.2
—
—
—
0
0
32
272
1.21
0.39
1.5
1.7
409.38
464.53
pmol/l
0.68
26
231
75
690
1.15
0.37
6.4
5.3
0.00
0.00
estimate
-0.00
13
133
12
92
1.33
0.32
1.0
1.0
—
—
—
0
0
74
689
1.12
0.29
4.6
3.8
0.00
0.00
estimate
-0.00
12
138
7
57
1.24
0.29
1.7
2.2
—
—
—
0
0
36
324
1.14
0.24
1.4
1.7
—
—
—
0
0
5
38
1.32
0.23
1.0
1.2
—
—
—
0
0
5
38
1.32
0.23
1.4
2.6
—
—
—
0
0
5
39
1.29
0.23
1.6
4.1
—
1.53
—
0
5
41
374
1.12
0.23
4.4
3.8
0.00
0.00
estimate
-0.00
11
126
5
40
1.26
0.22
1.8
2.6
—
—
—
0
0
32
288
1.13
0.22
4.7
4.9
1.79
3.23
ug/l
0.66
25
259
8
102
0.77
0.21
1.5
1.5
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
0
13
0.00
0.21
0.0
1.5
—
4.22
—
0
13
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
9
113
0.79
0.20
2.4
1.7
—
—
—
0
0
23
204
1.15
0.19
1.8
2.1
—
—
—
0
0
8
69
1.17
0.16
2.5
3.1
1.36
1.25
%
—
8
69
12
140
0.85
0.16
2.3
1.9
—
—
—
0
0
25
227
1.12
0.15
1.9
2.3
—
—
—
0
0
7
90
0.77
0.15
1.0
1.3
—
—
—
0
0
19
172
1.12
0.12
3.3
2.8
0.67
0.77
ug/l
0.15
14
118
26
250
1.05
0.03
1.4
1.3
1.84
10.33
u/ml
—
5
103
23
231
1.00
0.00
5.2
4.4
27.78
22.34
%
—
9
111
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
9.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
3.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
1537.50
—
0
6
0
8
0.00
-0.00
0.0
3.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
59.57
—
0
7
Mortality – FinRegistry
↥Association
Association between endpoint H7_MILDVISIMPBINOC and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| H7_MILDVISIMPBINOC | 1.814 [1.3, 2.54] | < 0.001 |
| Birth year | 0.997 [0.99, 1.01] | 0.541 |
During the follow-up period (1.1.1998 — 31.12.2019), 182 out of 791 females with H7_MILDVISIMPBINOC died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| H7_MILDVISIMPBINOC | 2.239 [1.54, 3.26] | < 0.001 |
| Birth year | 0.986 [0.98, 1.0] | 0.004 |
During the follow-up period (1.1.1998 — 31.12.2019), 181 out of 685 males with H7_MILDVISIMPBINOC died.
Mortality risk
Mortality risk for people of age
years, who have H7_MILDVISIMPBINOC.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.192% | 0.38% |
| 5 | 1.068% | 2.285% |
| 10 | 2.739% | 5.686% |
| 15 | 5.429% | 11.097% |
| 20 | 9.766% | 18.066% |
Relationships between endpoints
↥Index endpoint: H7_MILDVISIMPBINOC – Mild or no visual impairment, binocular
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data